Mia Elena Koponen

Mia Elena Koponen

Auto-generated profile, based on publicly available information

Mia Elena Koponen


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMia Elena Koponen
Mia Elena Koponen
Patrice ForgetPatrice Forget
Patrice Forget
Background: Opioid analgesics are the most effective pharmacological agents for moderate and severe pain. However, opioid use has several limitations such as opioid-induced hyperalgesia (OIH), which refers to the increased pain sensitivity that occurs once analgesia wears off after opioid administration. Several pharmacological interventions have been suggested for OIH, but the current literature does not provide guidelines on which interventions are the most effective and whether they differ depending on the opioid that induces hyperalgesia. This scoping review aimed to identify and describe all the preclinical trials investigating pharmacological interventions for OIH caused by remifentanil, fentanyl, or morphine as the first step towards evaluating whether the most effective OIH interventions are different for different opioids. Methods: Electronic database searches were carried out in Embase, PubMed, and Web of Science. Detailed data extraction was conducted on the eligible trials. Results: 72 trials were eligible for the review. Of these, 27 trials investigated remifentanil, 14 trials investigated fentanyl, and 31 trials investigated morphine. A total of 82 interventions were identified. The most studied interventions were ketamine (eight trials) and gabapentin (four trials). The majority of the interventions were studied in only one trial. The most common mechanism suggested for the interventions was inhibition of N-methyl-D-aspartate (NMDA) receptors. Conclusion: This scoping review identified plenty of preclinical trials investigating pharmacological interventions for OIH. Using the current literature, it is not possible to directly compare the effectiveness of the interventions. Hence, to identify the most effective interventions for each opioid, the interventions must be indirectly compared in a meta-analysis.

22 October 2024 in British Journal of Anaesthesia
Verified
Journal Article
Open access
DSDhaneesha N.S. Senaratne
Dhaneesha N.S. Senaratne
MKMia Koponen
Mia Koponen
KBKaren Barnett
Karen Barnett
BSBlair Smith
Blair Smith
THTim G. Hales
Tim G. Hales
LCLesley A. Colvin
Lesley A. Colvin
There is well-established evidence linking adverse childhood experiences (ACEs) and chronic pain in adulthood. It is less clear how ACE exposure might influence the response to chronic pain treatment. In this systematic review, we synthesise the literature assessing the impact of ACE exposure on outcomes relating to the use, benefits, and harms of analgesic medications (analgesia-related outcomes). We searched seven databases from inception to September 26, 2023, for studies investigating adverse events in childhood (<18 yr) and any analgesia-related outcome during adulthood (≥18 yr). Title/abstract screening, full-text review, data extraction, and risk of bias assessment were performed independently by two authors. Given the high degree of study heterogeneity, a narrative synthesis was performed. From 7531 records, 66 studies met inclusion criteria, involving 137 395 participants. Analgesia-related outcomes were classed into six categories: use of analgesics (n=12), analgesic side-effects (n=4), substance misuse (n=45), lifetime drug overdose (n=2), endogenous pain signalling (n=4), and other outcomes (n=2). No studies assessed the effect of ACE exposure on the potential benefits of analgesics. ACE exposure was associated with greater use of analgesic medication, higher incidence of analgesic medication side-effects, greater risk and severity of substance misuse, greater risk of drug overdose, and greater risk of attempted suicide in opioid dependency. Adverse childhood experience exposure is associated with poor analgesia-related outcomes, so individual assessment adverse childhood experiences is important when considering the treatment of chronic pain. However, significant gaps in the literature remain, especially relating to the use and harms of non opioid analgesics. CRD42023389870 (PROSPERO).

5 December 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMia E Koponen
Mia E Koponen
ENEmily Naray
Emily Naray
THTim G Hales
Tim G Hales
PFPatrice Forget
Patrice Forget
Background: To improve perioperative pain management, several interventions have been suggested for the prevention of increased pain sensitivity caused by opioids (called opioid-induced hyperalgesia). It is currently unclear which intervention is the most effective or appropriate in preventing opioid-induced hyperalgesia. Remifentanil is the most investigated opioid causing opioid-induced hyperalgesia. Thus, to guide future research, we conducted a systematic review and a network meta-analysis of preclinical trials investigating pharmacological interventions for remifentanil-induced hyperalgesia. Methods: To identify relevant articles, electronic database searches were conducted in Embase, PubMed, Web of Science, and Google Scholar. Study characteristics were extracted, and the risk of bias was evaluated. Studies were included in the network meta-analysis if they shared similar characteristics with at least one other study. The interventions were ranked based on P-scores. Results: Overall, the 62 eligible trials tested 86 individual interventions and 6 combination interventions. Thirty-five studies eligible in the network meta-analysis formed five groups which were further divided into subgroups based on the quantitative sensory tests used. The best-ranked interventions within the subgroups were Anxa12-26, MRS2179, salicylaldehyde isonicotinoyl hydrazone (SIH), ANA-12, TDZD-8, ketamine, dexmedetomidine, JWH015, and the combination of KN93 and ketamine. Discussion: The current literature is too heterogeneous to produce a clear answer on which intervention is the most effective in preventing remifentanil-induced hyperalgesia. Future research in this field should prioritise finding the most effective intervention over testing the efficacy of new options. The results of our work can be used in planning which comparisons should be included in new trials.

27 November 2025 in British Journal of Anaesthesia
Verified
Journal Article
Open access
MKMia E. Koponen
Mia E. Koponen
DSDhaneesha N.S. Senaratne
Dhaneesha N.S. Senaratne
HHHarry L. Hébert
Harry L. Hébert
BSBlair Smith
Blair Smith
LCLesley A. Colvin
Lesley A. Colvin
Pharmacoepidemiological studies show that large proportions of people with neuropathic pain are not prescribed the recommended medications, do not adhere well to these medications, and often discontinue the treatment within 6 months. Identifying what predicts these outcomes can inform a strategy to ensure that people with neuropathic pain are prescribed recommended medication and continue their treatment when appropriate. We carried out a systematic review and meta-analysis to identify predictors of pain medication prescribing, adherence, and discontinuation in adults with neuropathic pain. Electronic searches were conducted in Embase, PubMed, Web of Science, and CINAHL Plus. We identified 69 relevant studies and divided them into non-mutually exclusive categories based on the outcomes they had investigated. There were 53 studies on prescribing, 14 on adherence, and 27 on discontinuation. Predictors associated with being prescribed recommended neuropathic pain medications included having a mental health disorder, diabetes mellitus, and White race. Predictors associated with better adherence included being prescribed serotonin-norepinephrine reuptake inhibitors compared with gabapentinoids or tricyclic antidepressants, dose titration, and implementing a medicine reminder. Predictors associated with a higher likelihood of discontinuation included being prescribed tricyclic antidepressants rather than other antidepressants and having a combination of neuropathic pain medications rather than monopharmacotherapy. There is a need to focus on improving neuropathic pain medication prescribing for ethnic minorities and people without diabetes mellitus. Adherence can be improved by using dose titration and medicine reminders. Prescribing monopharmacotherapy rather than combination pharmacotherapy for neuropathic pain could result in better treatment persistence. PROSPERO (CRD42023464307).

4 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MKMia Elena Koponen
Mia Elena Koponen
DSDhaneesha N. S. Senaratne
Dhaneesha N. S. Senaratne
HHHarry Lidstone Hebert
Harry Lidstone Hebert
BSBlair Smith
Blair Smith
LCLesley A. Colvin
Lesley A. Colvin
Background Pharmacoepidemiological studies show that large proportions of people with neuropathic pain (NP) are not prescribed the medications recommended for NP, do not adhere well to these medications, and/or often discontinue the treatment within half a year. Identifying what predicts these outcomes can inform a strategy to ensure that people with NP are prescribed recommended medication and continue their treatment when appropriate. Methods We carried out a systematic review and meta-analysis to identify predictors of pain medication prescribing, adherence, and discontinuation in adults with NP (PROSPERO ID: CRD42023464307). Electronic searches were conducted in Embase, PubMed, Web of Science, and CINAHL Plus. Results We identified 60 relevant studies and divided them into non-mutually exclusive categories based on the outcomes they had investigated. There were 45 studies on prescribing, 14 on adherence, and 25 on discontinuation. Predictors associated with being prescribed recommended NP medications as the first choice included white ethnicity, having diabetes, and/or having a mental health disorder. Predictors associated with better adherence included being prescribed serotonin-norepinephrine reuptake inhibitors compared to gabapentinoids or tricyclic antidepressants; dose titration, and/or implementing a medicine reminder. Predictors associated with a higher likelihood of discontinuation included being prescribed medications other than second-generation antidepressants and/or having a combination of NP medications rather than a single medication. Conclusions Thus, there is a need to focus on improving NP medication prescribing for ethnic minorities and people with non-diabetic NP. Adherence and persistence with NP medications could be improved by prioritising the prescribing of serotonin-norepinephrine reuptake inhibitors if indicated.